Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v21-FR | Version v16-EN | |
|---|---|---|
| Language | French | English |
| Date Updated | 2023-11-15 | 2023-08-28 |
| Drug Identification Number | 00028096 | 00028096 |
| Brand name | CELESTONE SOLUSPAN | CELESTONE SOLUSPAN |
| Common or Proper name | BETAMETHASONE SODIUM PHOSPHATE AND BETAMETHASONE ACETATE SUSPENSION USP GLUCOCORTICOID | BETAMETHASONE SODIUM PHOSPHATE AND BETAMETHASONE ACETATE SUSPENSION USP GLUCOCORTICOID |
| Company Name | ORGANON CANADA INC. | ORGANON CANADA INC. |
| Ingredients | BETAMETHASONE BETAMETHASONE ACETATE | BETAMETHASONE BETAMETHASONE ACETATE |
| Strength(s) | 3MG 3MG | 3MG 3MG |
| Dosage form(s) | SUSPENSION | SUSPENSION |
| Route of administration | INTRAMUSCULAR INTRADERMAL INTRABURSAL INTRA-ARTICULAR INTRAMUSCULAR INTRADERMAL INTRABURSAL INTRA-ARTICULAR | INTRAMUSCULAR INTRADERMAL INTRABURSAL INTRA-ARTICULAR INTRAMUSCULAR INTRADERMAL INTRABURSAL INTRA-ARTICULAR |
| Packaging size | 5ML VIAL | 5ML VIAL |
| ATC code | H02AB | H02AB |
| ATC description | CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN | CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN |
| Reason for shortage | Disruption of the manufacture of the drug. | Disruption of the manufacture of the drug. |
| Anticipated start date | 2023-04-21 | 2023-04-21 |
| Actual start date | 2023-03-29 | 2023-03-29 |
| Estimated end date | 2023-11-17 | 2023-11-10 |
| Actual end date | 2023-11-15 | |
| Shortage status | Actual shortage | Actual shortage |
| Tier 3 Status | No | No |
| Company comments | ||
| Health Canada comments |